MedTrace Logo

Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients

NCT02981199 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-12-16

No results posted yet for this study

Summary

Comparison of the efficacy and safety of microtransplantation and autologous transplantation in the treatment of ≥PR multiple myeloma patients, 2-year PFS and OS were also been observed. To identify the role of microtransplantation in the treatment of multiple myeloma.

Conditions

  • Microtransplantation
  • Autologous Stem Cell Transplantation
  • Multiple Myeloma in Relapse

Interventions

PROCEDURE

stem cell transplantation

conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion

Sponsors & Collaborators

  • 307 Hospital of PLA

    collaborator OTHER

  • Chen Wenming

    lead OTHER

Principal Investigators

  • Wenming Chen, doctor · Beijing Chao Yang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02981199 on ClinicalTrials.gov